Clinical Trial Update: Active Symptom Control Alone Or In Combination With Oral Topotecan In Patients With Relapsed Resistant Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A completed Phase 3 trial comparing Active Symptom Control alone versus with oral topotecan in patients with relapsed resistant small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Hycamtin (Topotecan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Small Cell | Phase 3 | Status: COMPLETED